Historical Valuation
Veracyte Inc (VCYT) is now in the Fair zone, suggesting that its current forward PS ratio of 6.11 is considered Fairly compared with the five-year average of -14.05. The fair price of Veracyte Inc (VCYT) is between 27.40 to 70.73 according to relative valuation methord.
Relative Value
Fair Zone
27.40-70.73
Current Price：43.56
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Veracyte Inc (VCYT) has a current Price-to-Book (P/B) ratio of 2.66. Compared to its 3-year average P/B ratio of 1.92 , the current P/B ratio is approximately 38.45% higher. Relative to its 5-year average P/B ratio of 2.28, the current P/B ratio is about 16.82% higher. Veracyte Inc (VCYT) has a Forward Free Cash Flow (FCF) yield of approximately 2.93%. Compared to its 3-year average FCF yield of 1.90%, the current FCF yield is approximately 54.14% lower. Relative to its 5-year average FCF yield of 0.74% , the current FCF yield is about 295.69% lower.
P/B
Median3y
1.92
Median5y
2.28
FCF Yield
Median3y
1.90
Median5y
0.74
Competitors Valuation Multiple
AI Analysis for VCYT
The average P/S ratio for VCYT competitors is 6.02, providing a benchmark for relative valuation. Veracyte Inc Corp (VCYT.O) exhibits a P/S ratio of 6.11, which is 1.5% above the industry average. Given its robust revenue growth of 13.82%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for VCYT
1Y
3Y
5Y
Market capitalization of VCYT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of VCYT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is VCYT currently overvalued or undervalued?
Veracyte Inc (VCYT) is now in the Fair zone, suggesting that its current forward PS ratio of 6.11 is considered Fairly compared with the five-year average of -14.05. The fair price of Veracyte Inc (VCYT) is between 27.40 to 70.73 according to relative valuation methord.
What is Veracyte Inc (VCYT) fair value?
VCYT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Veracyte Inc (VCYT) is between 27.40 to 70.73 according to relative valuation methord.
How does VCYT's valuation metrics compare to the industry average?
The average P/S ratio for VCYT's competitors is 6.02, providing a benchmark for relative valuation. Veracyte Inc Corp (VCYT) exhibits a P/S ratio of 6.11, which is 1.50% above the industry average. Given its robust revenue growth of 13.82%, this premium appears unsustainable.
What is the current P/B ratio for Veracyte Inc (VCYT) as of Jan 09 2026?
As of Jan 09 2026, Veracyte Inc (VCYT) has a P/B ratio of 2.66. This indicates that the market values VCYT at 2.66 times its book value.
What is the current FCF Yield for Veracyte Inc (VCYT) as of Jan 09 2026?
As of Jan 09 2026, Veracyte Inc (VCYT) has a FCF Yield of 2.93%. This means that for every dollar of Veracyte Inc’s market capitalization, the company generates 2.93 cents in free cash flow.
What is the current Forward P/E ratio for Veracyte Inc (VCYT) as of Jan 09 2026?
As of Jan 09 2026, Veracyte Inc (VCYT) has a Forward P/E ratio of 27.39. This means the market is willing to pay $27.39 for every dollar of Veracyte Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Veracyte Inc (VCYT) as of Jan 09 2026?
As of Jan 09 2026, Veracyte Inc (VCYT) has a Forward P/S ratio of 6.11. This means the market is valuing VCYT at $6.11 for every dollar of expected revenue over the next 12 months.